SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Theodore Roosevelt

PatientTheodore Roosevelt
Date of birth2002-10-27
IdentifiersMRN HR-NI012-SYN; SSN (made up) 000-12-6157
Document date2026-06-08
AuthorAmos Kettering, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Three-month asthma review with repeat spirometry. [S]

History of Present Illness

Mr. Roosevelt returns three months after starting maintenance-and-reliever therapy. Since the four-week review he has had no night waking and daytime symptoms about once a week. He uses one as-needed inhalation before training and rarely any other. He has not missed an evening dose since setting a reminder. The bedding covers are in place. His home peak flow has settled between 590 and 610 L/min, so 610 is his personal best. He is back to full boxing, rowing, and a long hill walk most weekends. No exacerbations, urgent visits, or oral corticosteroids. [S]

ElementDetail
Interval changeNo night waking; symptoms about once a week
Reliever useOne inhalation before training; rarely otherwise
AdherenceAll maintenance doses taken since setting a reminder
Home peak flow590 to 610 L/min; personal best 610
FunctionFull training
ExacerbationsNone since starting controller therapy

Review of Systems

SystemResultFinding
RespiratoryNegativeNo night cough or wheeze; breathless only at the end of hard rowing pieces
Ears, nose, mouth, and throatNegativeNo hoarseness or sore mouth
MusculoskeletalNegativeNo injuries from training

3 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Albuterol 90 mcg/actuation inhaler, two inhalations as needed for wheeze (bought after an urgent care visit; used most days before intake)Two inhalations every 4 hours as neededRespiratory tract route2025-12-15 to 2026-03-09stoppedS
Budesonide-formoterol 160/4.5 mcg inhaler, two inhalations twice daily for maintenanceTwo inhalations twice daily, with a spacer, rinsing the mouth afterwardsRespiratory tract route2026-03-09activeS
Budesonide-formoterol 160/4.5 mcg inhaler, one inhalation as needed for symptoms and before exercise; no more than 12 inhalations a day in totalOne inhalation as needed, repeated after a few minutes if needed; maximum 12 inhalations a day including maintenance dosesRespiratory tract route2026-03-09activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-06-08Body height175cmS
2026-06-08Body weight73kgS
2026-06-08Body mass index (BMI) [Ratio]23.8kg/m2S
2026-06-08Systolic blood pressure118mm[Hg]S
2026-06-08Diastolic blood pressure74mm[Hg]S
2026-06-08Heart rate70/minS
2026-06-08Respiratory rate14/minS
2026-06-08Body temperature36.6CelS
2026-06-08Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-06-08FEV13.98L>=3.65 LNormalS
2026-06-08FEV1 measured/predicted89%>=80%NormalS
2026-06-08Forced vital capacity [Volume] Respiratory system5.02L>=4.4 LNormalS
2026-06-08FEV1/FVC0.79{ratio}>=0.72NormalS
2026-06-08Maximum expiratory gas flow Respiratory system airway by Peak flow meter605L/min80 percent or more of his personal best of 610 L/min (green zone)NormalS
2026-06-08Total score [ACT]22{score}S

Physical Exam

Vital signs recorded on 2026-06-08; see the Vital Signs section. [S]

SystemFinding
GeneralWell
MouthNo thrush
LungsClear, with no wheeze on forced expiration
Inhaler techniqueCorrect with his own inhaler and spacer

Problems

ProblemClinical statusVerificationCodeProvenance
Moderate persistent asthma, uncontrolled at intake, with reversible airflow obstruction on spirometry; synthetic modern diagnosis linked to his documented lifelong asthmaactiveconfirmed J45.40S — Synthetic modern classification confirmed by spirometry; the historical asthma is D and its persistence into adulthood is R.
Myopia, both eyes, corrected with glasses since boyhoodactiveconfirmed H52.13S — Synthetic modern entry linked to his documented near-sightedness.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
SurveyAsthma Control TestEvery visitCompleted today22, well controlled
ExaminationSpirometryAt diagnosis, 3 to 6 months after stabilization, then every 1 to 2 yearsCompleted todayFEV1 3.98 L, 89 percent predicted; FEV1/FVC 0.79; FVC 5.02 L
ExaminationPeak flow and personal bestDaily or with symptoms for moderate to severe asthmaCompleted today605 L/min in clinic; personal best 610 L/min
ExaminationInhaler technique with his own deviceEvery visitCompleted todayCorrect
Medication safetyAdherence and reliever useEvery visitCompleted todayFull adherence; reliever before training only
SurveyExacerbation historyEvery visitCompleted todayNone since starting controller therapy
Self-managementTrigger and exposure review, smoking and vaping statusEvery visitCompleted todayBedding covers in place; never smoker
Self-managementWritten asthma action planEvery visit and after every exacerbationCompleted todayZones reset to the confirmed personal best
SurveyStep-up or step-down assessmentEvery visitCompleted todayControlled for about two months; reassess for step-down at the six-month review
LaboratoryFeNO and blood eosinophilsAs indicatedNot indicatedPhenotyping completed at the four-week review; no diagnostic uncertainty
ReferralBiologic candidacy assessmentOnly if severe and uncontrolled despite optimized Step 4 to 5 therapyNot indicatedWell controlled at Step 4
Medication safetyVaccination statusYearlyUp to datePCV20 given at the four-week review; influenza vaccine due in the autumn

Goal progress:

Guideline basis: Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020); CMID: Clinical Monitoring Intelligence Database, asthma monograph (2026)

Follow-up: Asthma review in three months, or within one week of any exacerbation. Next scheduled visit 2026-09-14: six-month asthma review after a summer exacerbation. [S]